Answers are grounded in this paper and cite their sources.
Objective We aimed to investigate the clinical characteristics and computed tomography (CT) findings associated with progression-free survival (PFS) in patients with stage IIIB–IV epidermal growth factor receptor ( EGFR )-mutant lung adenocarcinoma (LAD) receiving tyrosine kinase inhibitors (TKIs) and to develop a model for PFS prediction and risk stratification. Materials and methods This retrospective study enrolled patients with stage IIIB–IV EGFR -mutant LAD who received TKI therapy and underwent pretreatment contrast-enhanced thoracic CT between January 2015 and April 2024. The Kaplan–Meier method was used to calculate the median survival time. The log-rank test was used to compare the differences in the survival curves between groups. The clinicoradiological findings associated with PFS were evaluated with a multivariate Cox regression model. The performance of the Cox regression model was assessed using the time-dependent area under the curve (AUC) and Harrell’s concordance index ( C -index). Non-parametric bootstrapping with 1,000 resamples was performed as internal validation to evaluate the robustness and discriminative ability of the model. Results A total of 242 patients (102 men and 140 women) with a mean age of 61 ± 11 years were included. The median PFS was 13 months. Multivariate analysis revealed that higher neuron-specific enolase (NSE, ≥18 ng/ml) (HR = 1.455), larger tumor size (≥5cm) (HR = 1.573), and the presence of liver metastasis (HR = 1.514) were associated with increased progression risk. On the other hand, treatment with third-generation EGFR-TKI therapy (HR = 0.694) and the presence of the vessel convergence sign (HR = 0.708) were associated with a significantly decreased risk of progression. We further constructed a nomogram based on the above five independent risk factors for predicting PFS. The C -index for predicting PFS was 0.623, and the AUCs for predicting the 6-, 12-, and 24-month PFS were 0.646, 0.676, and 0.699, respectively. The high-risk and low-risk groups were significantly different ( p < 0.001), with an HR of 1.931. The internally validated corrected global C -index was 0.610, and the AUCs for predicting the 6-, 12-, and 24-month PFS were 0.635, 0.671, and 0.695, respectively. Conclusion A nomogram based on baseline clinicoradiological factors serves as a useful tool for predicting PFS and stratifying risk in patients with advanced EGFR -mutated LAD after TKI therapy.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: